(RTTNews) - Roche (RHHBY) announced new late-breaking data from the ongoing Phase III IMAgINATION study showing that its investigational therapy sefaxersen delivered a statistically significant and clinically meaningful reduction in proteinuria in adults with primary IgA nephropa

Roche Reports Positive Phase III Data For Investigational IgAN Therapy Sefaxersen 

On October 23, 2026, Ionis Pharmaceuticals, Inc. issued a press release reporting that its partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demons

Ionis Pharmaceuticals, Inc. Partner Roche Announces Positive Phase 3 IMAgINATION Data for Sefaxersen in IgA Nephropathy

Ionis Pharmaceuticals, Inc. reported that its partner, GSK, announced that the U.S. Food and Drug Administration has approved HIBSAGO for the treatment of chronic hepatitis B virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor therapy in adu

Ionis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% Royalties

Key PointsAlnylam's stock has plunged more than 40% this year, but the company's financials look great.

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

Fintel reports that on October 15, 2026, UBS upgraded their outlook for Ionis Pharmaceuticals (NASDAQGS:IONS) (LSE:0JDI) from Neutral to Buy.Prior to this rating action, the stock closed at $42.70 on October 14, 2026. Following the action, the next-session close was recorded at $

UBS Upgrades Ionis Pharmaceuticals to Buy from Neutral

(RTTNews) - The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment

FDA Drug Approvals In September 2026 

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals, Inc. News